News | Contrast Media | May 16, 2023

VUEWAY (gadopiclenol) solution for injection and VUEWAY (gadopiclenol) Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 20231

VUEWAY (gadopiclenol) solution for injection and VUEWAY (gadopiclenol) Pharmacy Bulk Package are available for use in the U.S. following the market launch in February 20231

May 16, 2023 — Bracco Imaging, an innovative world leader delivering end-to-end products and solutions through a comprehensive portfolio inclusive of precision diagnostic imaging modalities, announced that the American College of Radiology (ACR) has classified VUEWAY (gadopiclenol) as a Group II agent within its classification of gadolinium-based contrast agents relative to the risk of development of nephrogenic systemic fibrosis (NSF).2

The ACR Committee on Drugs and Contrast Media states that, "Gadopiclenol demonstrates kinetic stability and a long dissociation half-life that is comparable to other Group II macrocyclic agents," and therefore considers that, "the risk of NSF among patients exposed to standard or lower than standard doses of gadopiclenol is sufficiently low or possibly nonexistent such that it has been classified as a Group II agent."2 

"We are pleased that the ACR Committee on Drugs and Contrast Media classified gadopiclenol as a Group II agent, in view of its very high stability, and made healthcare professionals aware of the low risk of NSF with this agent," said Alberto Spinazzi, MD, Chief Medical and Regulatory Officer at Bracco. "We are encouraged by the steady stream of medical institutions who have added VUEWAY injection to their formulary in view of the high stability and high relaxivity of this agent, and the benefit it provides to patients. We look forward to its continued adoption across the U.S. and globally, as we work towards regulatory approvals in other countries."

VUEWAY injection is approved for use in adult and pediatric patients aged 2 years and older with magnetic resonance imaging (MRI) of the CNS (brain, spine, and surrounding tissues) and the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system) at the dose of 0.05 mmol/kg.1

For more information: www.vueway.com

References:

1 Vueway (gadopiclenol) solution for injection Full Prescribing Information and Patient Medication Guide. Monroe Twp., NJ: Bracco Diagnostics Inc.; September 2022.

2 American College of Radiology. ACR Manual on Contrast Media. 2023.

Related content:

VIDEO: Talking Trends with Bracco: Investing in the Future of Radiology

Bracco and Guerbet Partner to Expand Access to Novel Imaging Agent

First Nationwide Use of Bracco's VUEWAY (gadopiclenol) Solution for Injection for MRI

Guerbet Announces Commercial Launch and First Patient Dosing of Elucirem (Gadopiclenol) Injection

Related Content of MRI Gadolinium Safety Concerns 

The Debate Over Gadolinium MRI Contrast Toxicity 

VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D. 

VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D. 

Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety 

Recent Developments in Contrast Media 

FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents 

European Medicines Agency Issues Update on Gadolinium Contrast Agents 

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents 

FDA: No Harm in MRI Gadolinium Retention in the Brain 

VIDEO: MRI Gadolinium Contrast Retention in the Brain 

Gadolinium May Remain in Brain After Contrast MRI


Related Content

News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | ACR

February 13, 2024 — The American College of Radiology (ACR) has announced that Mark Alson, MD, FACR, RCC, was presented ...

Time February 13, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | ACR

February 6, 2024 — An update to the CT Colonography Reporting and Data System (C-RADS) has been published Jan. 30 in the ...

Time February 06, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiation Oncology

January 30, 2024 — The largest professional societies representing radiation oncology physicians in the United States ...

Time January 30, 2024
arrow
News | Artificial Intelligence

January 22, 2024 — The Radiological Society of North America (RSNA), with the American College of Radiology (ACR) and ...

Time January 22, 2024
arrow
Subscribe Now